Related Experiment Video

Updated: Jul 5, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Use of lipid-modulating drugs in complicated course of coronary heart disease

N A Gratsianskii1, N A Vaulin

  • 1Laboratory of Clinical Cardiology, Institute of Physicochemical Medicine, Federal Agency on Health Care and Social Development, Moscow.

Bulletin of Experimental Biology and Medicine
|May 7, 2008
PubMed

Insights

This study evaluated lipid-modulating drugs in coronary heart disease. Statins showed benefits in acute coronary syndrome, but only safety was confirmed in heart failure.

Area of Science:

  • Cardiology
  • Pharmacology
  • Biochemistry

Background:

  • Coronary heart disease (CHD) poses significant health challenges.
  • Lipid-modulating drugs are crucial for managing cardiovascular risk.
  • Complicated CHD encompasses conditions like acute coronary syndrome (ACS) and chronic heart failure (CHF).

Purpose of the Study:

  • To investigate the efficacy and safety of lipid-modulating drugs in complicated coronary heart disease.
  • To assess the effects of statins (pravastatin, atorvastatin, simvastatin) and a fibrate (gemfibrozil) in ACS and CHF patients.

Main Methods:

  • The study involved patients with complicated coronary heart disease.
  • Lipid-modulating drugs, including specific statins and gemfibrozil, were administered.
  • Key clinical and biochemical parameters were monitored.

Main Results:

  • Statins demonstrated a positive impact on certain parameters in patients with acute coronary syndrome without ST elevation.
  • In patients with chronic heart failure, only the safety of short-term statin therapy was established.
  • Gemfibrozil's specific effects were not detailed in the provided abstract.

Conclusions:

  • Statins may offer therapeutic benefits in acute coronary syndrome.
  • Short-term statin use appears safe in chronic heart failure patients.
  • Further research is needed to fully elucidate the role of lipid-modulating drugs in diverse CHD populations.

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...